Aileron Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Rein Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 20, 2026, to address key corporate matters including director elections and a significant increase in authorized shares.
A company has reduced its quorum requirement for its annual stockholder meeting from a majority to 40% after failing to achieve a quorum at its initially scheduled meeting.
Rein Therapeutics announced the adjournment of its 2025 annual meeting of stockholders to July 23, 2025, due to a failure to achieve a quorum, urging stockholders to vote on pending proposals.
Rein Therapeutics will hold its annual meeting on June 24, 2025, seeking stockholder approval for the election of a Class II director and executive compensation.
Rein Therapeutics announces its 2025 annual meeting of stockholders to be held virtually on June 24, 2025, to vote on director election and executive compensation.
Aileron Therapeutics announces its annual stockholder meeting to be held on August 20, 2024, featuring proposals including the election of directors and ratification of the company's accounting firm.
Aileron Therapeutics will hold its 2024 annual meeting of stockholders virtually on August 20, 2024, to vote on director elections, executive compensation, and auditor ratification.